Bullish
Crinetics Pharmaceuticals (CRNX) recently presented new data at the ENDO 2026 meeting for its acromegaly drug PALSONIFY and investigational ACTH recep...
Neutral
GW&K Investment Management LLC boosted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 73.6% in the fourth qu...
Crinetics Pharmaceuticals, Inc. announced that it will present six abstracts, including oral presentations on PALSONIFY (paltusotine) and investigatio...